Home‎ > ‎


Proxeom is an early stage company started in 2016 with initial investments to develop and submit intellectual property applications in the field of liquid biopsy followed by the commercial release of reagents used in the development and validation of high sensitivity next generation sequencing assays in early 2017.

Proxeom is staffed with leadership experienced in developing and bringing Next Generation Sequencing products to market as well as with setting up and operating early stage companies. A substantial proportion of the initial laboratory work is performed by scientists on contract to Proxeom. 

Abizar Lakdawalla, PhD, the CEO and co-founder, brings a strong depth of genomics product development and product management experience. He defined and developed sequencing applications at Thermo Fisher Scientific such as liquid biopsy resulting in the commercialization of Oncomine circulating tumor DNA products. At Illumina, he defined the HiSeq sequencing systems that dominate the next generation sequencing landscape. He then moved to Illumina Europe, where he evangelized the adoption of next gen sequencing to a broad community of research and clinical scientists. Back at Illumina USA, he worked on a simplified sequencer based on camera-free light based detection and on the NextSeq sequencing platform that delivered high performance at a substantially reduced price point. 

Azra Jabeen, MBAis the President and co-founder of Proxeom with compelling business and financial expertise. Azra was instrumental in the runaway success of an early stage informatics company, NetClass, managing its business operations and customer relationships. She has held senior corporate financial roles at the marketing departments of Symantec and Hewlett Packard. She was the integration CFO of an IT security company in the UK and is currently the Global IT CFO at HPE. 

Gregory Boggy, PhD, is a founding partner, with expertise in Biological Systems Engineering of microorganisms, bioinformatics and quantitative genomics analyses. He has capitalized his expertise into developing automated bioassay workflows at Transcriptic; developed and managed solution-phase DNA capture probes used for targeted next generation sequencing applications based on photolithographic synthesis (Mycroarray); and developed a breakthrough quantitative analysis method for low count DNA detection at DNA software.

Eric E, PhD, is a founding partner, with strong research and commercialization backgrounds in molecular biology products. His PhD from Stanford focused on vesicle trafficking. He has experience in bringing a therapeutics startup up from the ground.

Arnold & Porter Kaye Scholer LLP, Palo Alto, California are our legal advisors.

Proxeom is looking for additional talented folks with strong skills in NGS library prep and bioinformatics. The wet-lab based positions are based in San Francisco at the QB3 incubator.

Please click on the following link to access the corporate presentation with details on markets served, revenue potentials, technology, commercialization phases and team profiles.

Corporate presentation (access requires password).